Mutants of Saccharomyces cerevisiae bearing lesions in the ergosterol biosynthetic pathway exhibit a pleiotropic drug-sensitive phenotype. This has been reported to result from an increased permeability of the membranes of the mutant strains to different drugs. As disruption of the yeast multidrug resistance protein, Pdr5p, results in a similar pleiotropic drug-sensitive phenotype, the possibility that Pdr5p may be functioning with a reduced efficiency in these altered sterol backgrounds was examined. To do this, the function of Pdr5p in isogenic strains of S. cerevisiae that have disruptions in the late stages of the ergosterol biosynthesis pathway (ERGG, ERG2, ERG3, ERG4) was studied. A reduced ability of Pdr5p to confer resistance to different drugs in these strains was observed, which did not appear to be dependent solely on the permeability of the membrane towards the drug. A simultaneous examination was made of how the lipid composition might be altering the efficiency of Pdr5p by similar studies in strains lacking phosphatidylserine synthase (encoded by CH09). The results indicated that the drug sensitivity of the erg strains is, to a significant extent, a result of the reduced efficiency of the Pdr5p efflux pump, and that the membrane environment plays an important role in determining the drug resistance conferred by Pdr5p.
INTRODUCTION
Multidrug resistance (MDR), the acquisition of simultaneous resistance to a wide variety of structurally and functionally unrelated compounds, is often associated with the overexpression of one or more members of a superfamily of ATP-binding cassette transporters (Gottesman & Pastan, 1993) . These proteins are comprised of 12 membrane-spanning a-helices and two ATP-binding domains (Borst & Schinkel, 1997) . MDR is a ubiquitous phenomenon and the membrane proteins responsible for this phenomenon are conserved throughout the evolutionary scale. The mechanism by which these proteins are able to confer resistance to such a structurally diverse range of compounds is still not known (Gottesman et al., 1996) . Structure-function 
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analyses from different groups (Loo & Clarke, 1993; Beaudet & Gios, 1995; Hanna et al., 1996; Kwan & Gros, 1998) have not identified any single domain that is responsible for the diverse substrate specificity of MDR pumps, although mutations affecting substrate specificity appear to be clustered around the transmembrane domains and the substrates have been shown to bind within the membrane bilayer (Sharom, 1997) .
The yeast Saccharomyces cerevisiae has also been shown to contain a MDR efflux pump, PdrSp, that belongs to the family of ABC transporters. Pdr5p has been cloned independently by several groups (Bissinger & Kuchler, 1994; Balzi et al., 1994; Hirata et al., 1994; Kralli et a/., 1995) and has been shown to confer resistance to a wide range of compounds and metal ions (Mahe et al., 1996) .
Overproduction of this protein confers pleiotropic drug resistance, whilst disruption of the gene encoding it leads to a pleiotropic drug-sensitive phenotype. Recent work with PdrSp, however, could not identify any single domain that affects the substrate specificity of this pump and it was suggested that the folded structure of the Pdr5p protein, and possibly the membrane composition, might play an important role in determining its substrate specificity (Egner et al., 1998) . Yeast erg mutants, which carry mutations in the ergosterol biosynthetic pathway, are resistant to antifungal antibiotics that target this pathway, but are otherwise pleiotropically drug-sensitive to a wide variety of structurally diverse compounds. This has been reported to be due to an increased permeability of their membranes to different drugs (Bard et al., 1978) . However, considering that disruption of the yeast PdrS pump also results in similar pleiotropic drug sensitvities, and the possible importance of the membrane environment in the functioning of these pumps, we decided to re-examine the drug-sensitive phenotypes of the erg mutants and investigate how the Pdr5 pump functions in these strains. An earlier investigation had repbrted that ergosterol, the major sterol of the yeast plasma membrane, inhibits the drug-binding ability of mammalian phosphoglycoproteins (P-gps) when expressed in yeast (Saeki et al., 1991) ; however, this has not been substantiated by later workers (Kuchler & Thorner, 1992) . A possible role of lipids in the modulation of the drug-binding activity of P-gps has been suggested by the observations that many characteristics of P-gps, including the pattern of ATPase stimulation or inhibition by drugs, is affected by the lipid environment (Doige et al., 1993; Saeki et al., 1992; Urbatsch & Senior, 1995) .
Our results, described in this report, indicate that the membrane environment/composition plays a significant role in determining the functioning of MDR pumps, and that the drug sensitivity of erg mutants is, to a large extent, due to the decreased drug efflux mediated by PdrSp in these strains.
METHODS
Chemicals. The chemicals used were of analytical grade. All media components were either purchased from HiMedia or Difco. Rhodamine 6G, cycloheximide, crystal violet, emetine and p-oestradiol were obtained from Sigma. Diphenylhexatriene (DPH) and trimethylammonium diphenylhexatriene (TMA-DPH) were obtained from Molecular Probes. Oligonucleotides were purchased from Ransom Hill Biosciences. Restriction/modification enzymes were obtained from New England Biolabs.
Yeast strains, media and growth conditions. The yeast strains used in this study are listed in Table 1 . They were grown at 30 "C and maintained on yeast extract/peptone/dextrose medium (YPD). YPD and synthetic media (SD) were prepared as described by Rose et al. (1990) .
Stock solutions of crystal violet, cycloheximide and emetine were prepared in water, whilst rhodamine 6G and p-oestradiol solutions were made in ethanol. Plates containing different compounds were made by adding the required volume of the stock solution of the compound to YPD medium during pouring.
Recombinant DNA methods. DNA manipulations including PCR were essentially carried out as described by Sambrook et al. (1989) . Yeast genomic DNA was isolated by the glass bead lysis method (Rose et al., 1990) . Yeast transformations were carried out by the lithium acetate method (Ito et al., 1983) .
Strain construction
(I) Construction of erg46 strain. Plasmid pCM2 containing the ERG4 gene disrupted with U R A 3 with flanking repeats (obtained from C. Marcireau, Rhone-Poulenc Rorer, VitrySur-Seine, France) was cleaved with SacIIHpaI and the 6.94 kb erg4A : : U R A 3 fragment was transformed into strain ABC 709 and selected for uracil prototrophy. The disruption at the ERG4 locus was confirmed by phenotypic analysis (drug sensitivity) and the U R A 3 region was popped out by selecting on 5-fluoroorotic acid plates, rendering erg4A a uracil auxotroph. The disruptant strain thus obtained was crossed with strain ABC 710 and tetrads were dissected to obtain an erg4A ABC 283 strain in a protease-deficient background.
(2) Construction of erg3A strain. The fragment containing erg3A::LEU2 was amplified from strain ABC 102 (erg3A : : LEU2, obtained from L. Parks, North Carolina State University, Raleigh, USA) with the primers for the flanking regions of this fragment. Strain ABC 287 [constructed from a cross of ABC 229 and ABC 710, which was used as a wild-type (wt) strain] was transformed with the purified, 2.4 kb PCR product and selected for leucine prototrophy. The disruptant ABC 261 was confirmed by phenotypic characterization and PCR.
(3) Construction of erg2A strain. The disruption of erg2A : : LEU2 was done by introducing a 2.2 kb LEU2 gene at the NdeI site within the coding region of ERG2 in the plasmid pFLA 2-7 (the plasmid was obtained from J. Heinisch, Heinrich Heine Universjtat, Dusseldorf, Germany). A 3.2 kb StuI-PstI fragment containing the erg2A : : LEU2 construct was used to transform strain ABC 709 to leucine prototrophy. The strain was confirmed for the disruption at the right locus by phenotypic analysis and PCR. The disruptant was mated with strain ABC 710 and tetrad dissection was done to obtain an erg2A strain (ABC 271) in a protease-deficient background.
(4) Construction of erg6A strain. An ERG6 (SED6) plasmid was obtained from H. Pelham, MRC, Cambridge, UK, and an ERG6 disruption was made by inserting a LEU2 fragment into the KpnI site of ERG6 that was first subcloned into the vector pGEX-2T. A 3.2 kb ScaI-BamHI fragment containing the erg6A: : LEU2 fragment was transformed into ABC 709 and selected for leucine prototrophy. The disruption at the ERG6 locus was confirmed by PCR. An erg6A strain (ABC 265) in a protease-deficient background was obtained by crossing the resultant disruptant with ABC 710 and subsequently dissecting tetrads.
(5) Construction of pdr5A strain. A diploid was made by crossing ABC 710 with ABC 152 (pdr5A: : TRPl) and a 3-2 kb ScaIBamHI fragment of the plasmid bearing erg6A: : LEU2 was transformed into the diploid strain. The transformants were selected for leucine prototrophy and then plated on the sporulation medium. Tetrad dissection was done to obtain a pdr5A (ABC 288) strain in a protease-deficient background.
(6) Construction of cholA strain. The chol A : : LEU2 strain was constructed by the PCR-mediated direct gene disruption method (Baudin et al., 1993) . The primers CHDELl ( 5' AAGTTCGACTACGTCGTAAGGCCG 3') and CHDEL2 AGTGGTAATGGAATCCCAACAATTACA 3') were used CACAGAGACGAAAATGACGGGTATGCCTCAGATG- for ma king the disruption. PCR was done from a LEU2-based plasmid, pSP1, and the 2.2 kb amplified product was used to transform ABC 287 strain to leucine prototrophy. The putative disruptant (leucine prototroph) (ABC 626) was checked for disruption by phenotypic analysis (choline auxotrophy) and PCR.
To construct strain choZA: : TRPl in a background that was not protease-deficient, PCR was done on strain ABC 706 (chol A : : TRPI) with CHFOR (5' TCACATGGACCCATC-TAAAGA 3') and CHREV (5' TTTGACGCCAGGCAT-GAACAA 3') primers. The amplified product (2.6 kb) having choZA: : TRPl was used to transform strain ABC 154 to tryptophan prototrophy.The disruption at the right locus was confirmed by phenotypic characterization and PCR in strain ABC 62.5.
Construction of plasmid.
The plasmid PDRS/YEplacl9.5 was constructed by digesting pSTSI (obtained from K. Kuchler, University and Biocenter of Vienna, Austria) with SphIIApaI, purifying the 7.5 kb fragment and cloning in the SmaI site of the niulticopy plasmid YEplacl95 (Gietz & Sugino, 1988) .
In vivo drug sensitivity assay. PdrSp-mediated resistance to different compounds was tested by spotting serial dilutions of yeast culture onto plates containing drugs.The transformants were pregrown in SD broth lacking uracil to late-exponential phase and then reinoculated into fresh medium to a cell concentration of 5 x lo6 cells ml-'. After incubation for 6-7 h at 30 "C, the optical density was measured at 600 nm and the number of cells per ml of culture was calculated. Serial dilutions containing lo7, lo', lo5 and lo4 cells mlF' were then made in sterile water and 10 pl of each serially diluted culture was spotted onto YPD plates containing either the solvent or the drug, and onto SD lacking uracil (SD -ura) selection plates to check for plasmid stability.
MIC estimations. The MIC of a drug was defined as the minimum concentration at which no growth was observed when 10 pl of the second dilution (i.e. 10, cells ml-') of a culture was spotted onto the plate containing the drug.
Rhodamine 6G efflux assay in whole cells. The rhodamine efflux study was essentially carried out as described by Kolaczkowski e t al. (1996) with a few modifications. The strains were pregrown in YPD broth for 12-14 h and then reinoculated into fresh media to an initial OD,,, of 0.2. After incubation for 5-6 h at 30 "C, equal numbers of cells from an exponential-phase culture were harvested, washed four times with water and resuspended (wet wt = 40mg) in 0.5 ml HEPES buffer (50 mM HEPES-NaOH, pH 7-0). 2-Deoxy-~-glucose and rhodamine 6G were added to a final concentration of 5 mM and 10 pM, respectively, and incubated at 25 "C for 2 h. After incubation, rhodamine-6G-loaded cells were quickly spun down, washed twice with HEPES buffer and finally resuspended in 4 ml HEPES buffer. The final suspension was aliquoted into two parts (2 ml each), 1 mM glucose was added to one aliquot to initate the active, PdrSp-mediated efflux of rhodamine 6G. The cell suspension was incubated at room temperature. At time zero, i.e. immediately after the additioii of glucose, a 0.5 ml sample was withdrawn from both aliquots (with and without glucose), cells were quickly spun down and the fluorescence of rhodamine extruded in the assay buffer was measured at an excitation and emission wavelength of 529 nm and 553 nm, respectively (slit width = 5) on a Perkin-Elmer LS 50 B spectrofluorimeter. After 7 and 21 min further incubation, a 0.5 ml sample was again withdrawn, cells were removed by centrifugation and the fluorescence of rhodamine 6G extruded in the supernatant was measured. spectrofluorimeter. The excitation and emission wavelengths were 360 nm and 450 nm, respectively. The measured fluorescence intensities were corrected for background fluorescence and light scattering from the unlabelled sample, i.e. the sample treated with the solvent alone. The degree of steady-state anisotropy (rs) was calculated as described by Haggerty et al. (1978) 
RESULTS

Effect of Pdr5p overexpression on drug resistance in erg strains
Strains with disruptions in the late steps of the ergosterol biosynthetic pathway are viable and accumulate sterols other than ergosterol in the membrane (Lees et al., 1995) . The predominant sterols that accummulate are the ones shown in Fig. 1 occur in the vacuole (Egner et al., 1995; Egner & Kuchler, 1996) .
PdrSp was overexpressed in different, erg strains by introducing the PDRS gene on a URA3-based multicopy plasmid, transforming the different erg strains with this plasmid, and then examining the resistance conferred to different drugs. We used drug resistance conferred by
PdrSp overexpression in these strains as a means of evaluating PdrSp function. Overexpression of PdrSp itself did not affect the growth of the strains relative to the vector only, nor were there any differences in plasmid stability in the different strains (data not shown).
We observed that all the erg strains showed an increased sensitivity to cycloheximide although to different extents (Fig. 2 ) . Control experiments without drugs, or with only the solvents in which the drugs were dissolved, were carried out in these and subsequent experiments, to eliminate any differences that might have occurred in the absence of drugs (data not shown). As additional controls, the resistance conferred in wt and pdr5A strains was also simultaneously determined and these data are included in all the figures. The erg6A and erg4A strains were the most sensitive, and the sensitivity of the pdr5A strain was also comparable to that of the erg6A and erg4A strains. The sensitivities of the strains are a reflection of the intracellular accumulation of the drug under steady-state conditions. When we overexpressed PdrSp in these strains, we found that overexpression of the PdrSp in these different strains did not lead to drug resistance to the same levels (Fig. 2) . PdrSp overexpression led to significantly higher levels of drug resistance in the erg46 strain as compared to the erg6A strain, and even as compared to the erg2A strain, which otherwise displayed lesser sensitivity. In the pdr5A U P U P U P U P U P U P V P U P U P U P U P V P ------------ 
Fig. 2.
Pdr5p-mediated cycloheximide resistance in wt, erg4A, erg3A, erg2A, erg6A and pdr5A strains of 5. cerevisiae.
Strains transformed either with the control plasmid YEplacl95 (U) or with the PDR5-overexpressing plasmid PDR5NEplac195 (P) were grown to exponential phase in SD-ura a t 30°C. An equal number of cells of each strain was harvested, resuspended in sterile water to a density of 1 x lo7 cells ml-' and 10 pl of undiluted cell suspension, 1 : 10, 1 : 100 and 1 : 1000 dilutions was spotted onto YPD plates containing different concentrations of cycloheximide. Growth was scored after 3 d incubation a t 30 "C. The growth pattern of the first two suspensions (lo7 and l o 6 cells ml-I) is shown in the first and second rows, respectively. strain, however, which otherwise has no altered sterols in the membrane, the level of resistance conferred was up to the wt levels. These results indicate firstly that alteration in the sterol content of the cells led to a decreased drug resistance conferred by PdrSp as compared to the cells having ergosterol in their membranes, and secondly that the decreased resistance was not a simple consequence of increased permeability and sensitivity of the strains to the drug.
To exiimine whether our observation with cycloheximide was a general phenomenon, we extended this study to other structurally unrelated drugs, crystal violet, emetine and oestradiol. The conclusions we reached with crystal violet (data not shown), were very similar to those with cycloheximide. In the case of emetine, however, PdrSp virtually failed to confer any significant resistance in erg6A and erg2A strain backgrounds (Fig. 3 ) , although it could mediate efflux of the drug in the other strain backgrounds. The results with oestradiol were interesting in that we were able to observe oestradiol toxicity for the first time in yeast using the erg6A strain. However, we observed that oestradiol toxicity could be effectively reversed even in an erg6A background by PdrSp overexpression (Fig. 4), indicating that PdrSp was functioning in this background to efflux some, but not all of the drugs.
Rhodamine 6G efflux in ergosterol-deficient strains of S. cerevisiae
Since the decreased drug resistance conferred by PdrSp was indirect evidence of PdrSp efficiency under steadystate conditions, we decided to measure PdrSp efficiency directly by monitoring the PdrSp-mediated efflux of rhodamine 6G in erg backgrounds at different time intervals.
Rhodamine 6G is a known substrate of PdrSp and is reported to be effluxed by PdrSp in an energy-dependent manner (Kolaczkowski et al., 1996) . T o check the functioning of PdrSp in altered sterol backgrounds, we carried out the rhodamine efflux assay in erg strains along with the wt and p d r 5 A strains serving as the positive and negative controls. The energy-dependent PdrSp-driven extrusion of rhodamine was initiated by the addition of 1 m M glucose and fluorescence of extruded dye in the assay buffer was measured after different time intervals. The erg4A, e r g 2 A and erg6A strains were found to efflux rhodamine 6G at a slower rate than the wt cells while e r g 3 A cells showed a relatively higher rate of efflux as compared to other erg strains (Table 2) . Rhodamine efflux was seen in the wt, e r g 4 A and e r g 3 A strains 7 min after glucose addition; however, very little efflux was seen in erg2A and erg6A strains after 7 min. We also examined the efflux after
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Oestrad iol Plasmid: 21 min. At this time point, both erg2A and erg6A cells were found to be able to efflux rhodamine in the presence of glucose. Very little release of rhodamine was seen at 21 min in the erg2A and erg66 mutants in the absence of glucose indicating that efflux was not due to mere leakage of the dye across the membranes. The cells lacking PdrSp (pdr5A strain) showed very low levels of active efflux of the dye even 21 min after glucose addition (Table 2 ). This experiment demonstrated that although PdrSp was functional in these strains, the altered sterol environment had a significant effect on its efflux capabilities.
Does Pdr5p function in erg strains correlate with membrane fluidity?
Alteration in sterol content of the membrane is known to primarily affect its fluidity. T o determine whether the differences in PdrSp efficiency that we observed in different strains was correlated with membrane fluidity, we measured the membrane fluidity of the strains. This was done with whole cells using both DPH and TMA-DPH as probes. The fluorescence anisotropies of these probes in membranes correlate inversely with membrane fluidity. Although we did observe an increase in membrane fluidity in erg mutants relative to the wt, we could not find any correlations between the membrane fluidity of these strains and the efficiency of the PdrSp pump (Table 3) . 
Pdr5p pump efficiency in a phosphatidylserinedeficient mutant
As alteration of the sterol composition led to a significant reduction in the ability of PdrSp to confer drug resistance, we wished to determine if alteration in the phospholipid composition of the membrane might also affect PdrSp efficiency. We therefore constructed a chol A strain in the same background. These cells are choline auxotrophs but are otherwise viable. CHOl encodes phosphatidylserine synthase and its disruption results in the membrane being completely devoid of phosphatidylserine (Hikiji et al., 1988) . The lack of phosphatidylserine is largely compensated for by an increase in the phosphatidylinositol and phosphatidylcholine levels (Atkinson et al., 1980) .
When we overexpressed PdrSp from a multicopy plasmid in such a cholA strain in a similar manner to that done for erg mutants, we observed that the plasmid bearing PDRS was highly unstable, making a comparison of the drug resistance profiles of PdrSp difficult to study (data not shown). We therefore carried out the analysis in a strain that is not deficient in the vacuolar proteases PEP4 and PRBl. In this background, the plasmid was stable, which allowed the comparison of Pdr5p oirerexpression in this strain (Fig. 5) .
The cho 1A strain was mildly resistant to cycloheximide as compared to the wt strain, as seen in Fig. 5 . Pdr5p overexpression in the c h o l A strain was, though, able to confer resistance to cycloheximide to a significant level ; however, it did not reach the wt levels of resistance.
In the case of crystal violet, the cholA strain was significantly more resistant as compared to the wt cells, PDRSREplacl95 (P). The wt transformants and the cholA transformants were grown to exponential phase in SD-ura broth and SD-ura broth supplemented with 1mM choline, repsectively. Cells were spotted onto plates of YPD, SD-ura containing 1 mM choline, and YPD containing different concentrations of cycloheximide as described in the legend to and the level of resistance conferred by Pdr5p was also significantly higher than that in the wt strain (Fig. 6 ). This drug selectivity indicates that lipid composition also plays a role in modulating the level of drug resistance conferred by the PdrSp pump, and in a drugspecific manner.
DISCUSSION
In this report, we have investigated whether the pleiotropic drug sensitivity of erg mutants might in part result from an altered functioning of the yeast MDR pump, PdrSp. These erg strains are used extensively in different drug-based studies (Graham et al., 1993; Hemenway & Heitman, 1996) and the tacit assumption has been that these strains are hyperpermeable to different drugs. However, the studies described in this report indicate that this assumption is not entirely valid and one also has to take into account the fact that the efflux pumps have a reduced efficiency in these backgrounds. We have not examined the localization of Pdr5p in these strains and it is possible that the reduced efficiency of Pdr5p in altered sterol backgrounds could be due to partial mislocalization of the protein. However, complete mislocalization had not ocurred since the pumps could mediate efflux of some of the drugs, although to lesser extents. Some other important conclusions may be drawn from this study. Firstly, the drug resistance profiles were affected in a manner that was dependent on both the strain background and the drug being tested.
Thus the erg6A strain could efflux some, but not all, of the drugs. This suggests that although the lipid bilayer is not the primary determinant for substrate specificity, it plays an important role in modulating this specificity in addition to modulating efficiency. Furthermore, previous studies have indicated that the ability of the MDR pump to mediate efflux of a drug depends on the permeability of the membrane to the drug (Eytan et al., 1996 (Eytan et al., , 1997 , but we observed that the reduced ability of PdrSp to efflux drugs in different strains is not dependent solely on the permeability of the membrane towards the drugs.
Our results also highlight the importance of evaluating the function and substrate specificity of MDR pumps over a range of drug concentrations to attain more complete resistance profiles.
The decreased efflux of drugs in the erg6A strain leading to the drug hypersensitivity phenotype is in contrast to the cation-sensitivity phenotype of this strain, where the Lit and Na' hypersensitivity was primarily due to increased uptake rather than the decreased efflux (Welihinda et al., 1994) . erg6A cells also exhibit defective tryptophan uptake, presumably due to a defect in tryptophan permease (Caber et al., 1989) . In addition to this, the transport kinetics of a few other permeases of yeast is also known to be affected by the lipid composition of the membrane (Keenan et al., 1982; Calderbank et al., 1985) .
Recently, Egner et al. (1998) have initated detailed studies of mutants of PdrSp with altered function by random mutagenesis. As mutants with altered substrate specificity were observed to occur in no single domains, and a few of the mutants were also found to have defects in folding, these authors have suggested a possible role for the folded structure of PdrSp as a major determinant of its diverse substrate specificity. Lipids have been shown to function as molecular chaperones (Bogdanov et al., 1996) and it is possible that in strains with altered lipid/ergosterol content, some defect in folding of membrane proteins may occur and that this might be partly responsible for both their altered efficiency and their altered substrate specificity.
The observation that PdrSp overexpression in a phosphatidylserine-deficient mutant in a proteasedeficient background led to significant differences in plasmid stability suggests that overexpression of this protein is, for some reason, deleterious to cells in this background. Mammalian P-gps have also been shown to destabilize membranes (Arsenault et al., 1988) and it may be interesting to examine whether the destabilization is affected by the composition of the membrane itself.
The present study, for the first time, reports that the reduced efficiency of the MDR pump, PdrSp, in S. cerevisiae erg strains is responsible to a significant extent for their pleiotropic drug-sensitive phenotypes. This observation is of great significance in view of the fact that the majority of antifungal compounds that are being extensively used to treat fungal infections inhibit the enzymes of the ergosterol biosynthetic pathway. Thus it will be very interesting to study whether the reduced efficiency of the MDR pumps of these yeasts might allow use of other drugs in combating the fungal infection. The present study, if extended to pathogenic yeast-like Candida spp., may shed some light on the complex drug resistance phenomenon of this yeast, and will stimulate further dissection of the role of the membrane in the functioning of MDR pumps.
